In Brief: Diagnostic Solutions safety alert
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Solutions safety alert: FDA notifies retailers and health care facilities nationwide on Oct. 11 that, despite a blood glucose test strip recall issued by Diagnostic Solutions in January and June 195, "FDA and the manufacturer have recently found recalled strips in some retail outlets and health care facilities, such as nursing homes." The strips pose a serious health risk to users, FDA says, because they may give inaccurate readings...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.